PEACE (Pegzilarginase Effect on Arginase 1 Deficiency Clinical Endpoints): A Randomized, Double-blind, Placebo-controlled Phase 3 Study of the Efficacy and Safety of Pegzilarginase in Children and Adults With Arginase 1 Deficiency
Phase of Trial: Phase III
Latest Information Update: 05 Dec 2019
Price : $35 *
At a glance
- Drugs Pegzilarginase (Primary)
- Indications Hyperargininaemia
- Focus Pharmacokinetics; Registrational
- Acronyms PEACE
- Sponsors Aeglea Biotherapeutics
- 29 Aug 2019 According to an Aeglea Biotherapeutics media release, trial design data will be presented as an e-poster at the 2019 Symposium of the Society for the Study of Inborn Errors of Metabolism (SSIEM) (in Rotterdam, the Netherlands, 6th Sep 2019).
- 03 Jun 2019 According to an Aeglea Bio Therapeutics media release, first patient has been dosed.
- 16 Apr 2019 Status changed from planning to recruiting.